Scarica l'app Stockscreener
1.475
4.22%
-0.065
Dopo l'orario di chiusura:
1.48
0.005
+0.34%
Precedente Chiudi:
$1.54
Aprire:
$1.5
Volume 24 ore:
58,290
Relative Volume:
0.92
Capitalizzazione di mercato:
$10.62M
Reddito:
-
Utile/perdita netta:
$-9.04M
Rapporto P/E:
-1.0064
EPS:
-1.4656
Flusso di cassa netto:
$-23.55M
1 W Prestazione:
-11.09%
1M Prestazione:
+1.03%
6M Prestazione:
-52.88%
1 anno Prestazione:
+10.07%
Intervallo 1D:
$1.45
$1.53
Intervallo di 1 settimana:
$1.45
$1.73
Portata 52W:
$0.8288
$3.855
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
Nome
Chemomab Therapeutics Ltd Adr
Settore
Industria
Telefono
972-77-331-0156
Indirizzo
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Compare CMMB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
1.475 | 11.09M | 0 | -9.04M | -23.55M | -1.4656 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-13 | Iniziato | Maxim Group | Buy |
| 2024-05-06 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-12-19 | Ripresa | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr Borsa (CMMB) Ultime notizie
Chemomab Therapeutics (CMMB) flags going-concern risk and reliance on nebokitug - Stock Titan
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB) and Reviva Pharmaceuticals Holdings (RVPH) - The Globe and Mail
Chemomab Therapeutics (CMMB) to Release Quarterly Earnings on Monday - Defense World
Pre Market Movers: DBVT, YCBD, KYTX Set The Pace - RTTNews
Chemomab Therapeutics (NASDAQ:CMMB) Shares Down 4.5% – Time to Sell? - Defense World
Chemomab’s nebokitug shows disease-modifying potential in PSC trial - Investing.com
Chemomab’s nebokitug shows disease-modifying potential in PSC trial By Investing.com - Investing.com UK
Chemomab Therapeutics (NASDAQ:CMMB) Cut to “Hold” at Zacks Research - Defense World
Chemomab reports positive 48-week data for PSC drug nebokitug - Investing.com
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - sharewise.com
Best Momentum Stocks to Buy for Oct. 23 - The Globe and Mail
New Strong Buy Stocks for Oct. 23: MQ, GES and More - Yahoo Finance
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study - Yahoo Finance
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis - Yahoo Finance
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs - Yahoo Finance
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan - Yahoo Finance
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer - Yahoo Finance
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Finviz
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder - Yahoo Finance
Chemomab Therapeutics (NASDAQ:CMMB) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - Finviz
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - Yahoo Finance
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases - Nasdaq
Chemomab Therapeutics Ltd Share Price ADR Each Representing 80 Ord Shares SPON - Hargreaves Lansdown
Oppenheimer raises Chemomab stock price target to $25 on M&A potential - Investing.com
Jeff Jones Analyst Performance at Oppenheimer - MarketBeat
KURA Stock Rises More Than 15% This Past Week: Here's Why - Yahoo Finance
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Nasdaq
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - The Globe and Mail
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Finviz
Aspire Biopharma (ASBP) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Chemomab Therapeutics to Present at October 2024 Investor Conferences By Investing.com - Investing.com
Entero Therapeutics (ENTO) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Chemomab Therapeutics (CMMB) Stock Trends and Sentiment 2025 - MarketBeat
Chemomab Therapeutics (CMMB) Stock Forecast and Price Target 2026 - MarketBeat
Chemomab Therapeutics Ltd. Sponsored ADR Earnings and Revenue – NASDAQ:CMMB - TradingView — Track All Markets
symbol__ Stock Quote Price and Forecast - CNN
Psyence Biomedical (PBM) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
GRI Bio (GRI) Short Interest & Short Float | Updated Apr 2026 $GRI - MarketBeat
Chemomab Therapeutics LtdADR (CMMB) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
What is the current Price Target and Forecast for Chemomab Therapeutics (CMMB) - Zacks Investment Research
IO Biotech (IOBT) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Chemomab Therapeutics (CMMB) 10K Form and SEC Filings 2026 - MarketBeat
Chemomab Therapeutics (CMMB) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
What date does Chemomab Therapeutics's (CMMB) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
What You Need To Know About Chemomab Therapeutics Ltd.'s (NASDAQ:CMMB) Investor Composition - Yahoo Finance
CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Technical Analysis - Chartmill
Chemomab Therapeutics (CMMB) Institutional Ownership 2026 - MarketBeat
CMMB: Chemomab Therapeutics LtdADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Chemomab Therapeutics Ltd. Sponsored ADR Financial Statements – NASDAQ:CMMB - TradingView
Chemomab Therapeutics Ltd Adr Azioni (CMMB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):